Tudóstér: Botó Pál publikációi

Kolostyák, Z., Bojcsuk, D., Baksa, V., Máthéné Szigeti, Z., Bene, K., Czimmerer, Z., Botó, P., Fadel, L., Póliska, S., Halász, L., Tzerpos, P., Berger, W., Villabona-Rueda, A., Varga, Z., Kovács, T., Patsalos, A., Pap, A., Vámosi, G., Bai, P., Dezső, B., Spite, M., D'Alessio,, F., Szatmári, I., Nagy, L.: EGR2 is an epigenomic regulator of phagocytosis and antifungal immunity in alveolar macrophages.
JCI Insight. 9 (17), 1-21, 2024.

Jambrovics, K., Botó, P., Pap, A., Sarang, Z., Kolostyák, Z., Czimmerer, Z., Szatmári, I., Fésüs, L., Uray, I., Balajthy, Z.: Transglutaminase 2 associated with PI3K and PTEN in a membrane-bound signalosome platform blunts cell death.
Cell Death Dis. 14 (3), 1-10, 2023.

Douida, A., Batista, F., Botó, P., Regdon, Z., Robaszkiewicz, A., Tar, K.: Cells Lacking PA200 Adapt to Mitochondrial Dysfunction by Enhancing Glycolysis via Distinct Opa1 Processing.
Int. J. Mol. Sci. 22 (4), 1-22, 2021.

Botó, P., Gerzsenyi, T., Lengyel, A., Szúnyog, B., Szatmári, I.: Zbtb46-dependent altered developmental program in embryonic stem cell-derived blood cell progenitors.
Stem Cells. 39 (10), 1322-1334, 2021.

Douida, A., Batista, F., Robaszkiewicz, A., Botó, P., Aladdin, A., Szenykiv, M., Czinege, R., Virág, L., Tar, K.: The proteasome activator PA200 regulates expression of genes involved in cell survival upon selective mitochondrial inhibition in neuroblastoma cells.
J. Cell. Mol. Med. 24 (12), 6716-6730, 2020.

Dániel, B., Czimmerer, Z., Halász, L., Botó, P., Kolostyák, Z., Póliska, S., Berger, W., Tzerpos, P., Nagy, G., Horváth, A., Hajas, G., Silye-Cseh, T., Nagy, A., Sauer, S., Francois-Deleuze, J., Szatmári, I., Bácsi, A., Nagy, L.: The transcription factor EGR2 is the molecular linchpin connecting STAT6 activation to the late, stable epigenomic program of alternative macrophage polarization.
Genes Dev. 34 (21-22), 1474-1492, 2020.

Aladdin, A., Király, R., Botó, P., Regdon, Z., Tar, K.: Juvenile Huntington's disease skin fibroblasts respond with elevated parkin level and increased proteasome activity as a potential mechanism to counterbalance the pathological consequences of mutant huntingtin protein.
Int. J. Mol. Sci. 20 (21), 1-39, 2019.

Botó, P., Csuth, T., Szatmári, I.: RUNX3-Mediated Immune Cell Development and Maturation.
Crit. Rev. Immunol. 38 (1), 63-78, 2018.

Takács, E., Botó, P., Simó, E., Csuth, T., Tóth, B., Raveh-Amit, H., Pap, A., Kovács, E., Kobolák, J., Benkő, S., Dinnyés, A., Szatmári, I.: Immunogenic Dendritic Cell Generation from Pluripotent Stem Cells by Ectopic Expression of Runx3.
J. Immunol. 198 (1), 239-248, 2017.

Kiss, M., Czimmerer, Z., Nagy, G., Bieniasz-Krzywiec, P., Ehling, M., Pap, A., Póliska, S., Botó, P., Tzerpos, P., Horváth, A., Kolostyák, Z., Dániel, B., Szatmári, I., Mazzone, M., Nagy, L.: Retinoid X receptor suppresses a metastasis-promoting transcriptional program in myeloid cells via a ligand-insensitive mechanism.
Proc. Natl. Acad. Sci. U. S. A. 114 (40), 10725-10730, 2017.

Bencsik, R., Botó, P., Szabó, R., Tóth, B., Simó, E., Bálint, B., Szatmári, I.: Improved transgene expression in doxycycline-inducible embryonic stem cells by repeated chemical selection or cell sorting.
Stem Cell Res. 17 (2), 228-234, 2016.